Condition: Acute Myeloid Leukemia · Blasts 20-30 Percent of Bone Marrow Nucleated Cells · Chronic Myelomonocytic Leukemia · Sponsor: M.D. Anderson Cancer Center
This phase II trial studies the side effects and how well azacitidine and enasidenib work in treating patients with IDH2-mutant myelodysplastic syndrome. Azacitidine and enasidenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
This description comes directly from the study's public registry record.
Courtney DiNardo, MD · 713-794-1141 · cdinardo@mdanderson.org
Always discuss trial participation with your own doctor first.
| Johns Hopkins University/Sidney Kimmel Cancer Center | Baltimore, Maryland, United States | Active Not Recruiting |
| Cleveland Clinic Foundation | Cleveland, Ohio, United States | Active Not Recruiting |
| M D Anderson Cancer Center | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03383575